• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

Stock-Specific Ideas for the Post-Fed Era of Investing

Make sure that your portfolio is composed of sane assets for the balance of this crazy year.
By JIM COLLINS
Sep 18, 2020 | 12:15 PM EDT
Stocks quotes in this article: MRNA, CVAC, BNTX, AZN, ARCT, CTLT, TSLA

Macro trumps micro.

Macro trumps micro. We learned that Thursday as stocks fell sharply into the red at the open and then after an attempt to find the breakeven line once again declined in the afternoon.

So, what is happening and how should you be playing it?

First and foremost, the market didn't hear what it wanted from Federal Reserve Chair Jerome Powell. As difficult as it is for me to explain the zeitgeist of a market that as recently as last week was willing to pay 23x earnings (a generational high and a level not seen since the dot-com bubble), I would summarize the market's reaction thusly: We are not hearing that things will be OK by year-end.

To their credit, FOMC members did not make any scientific claims regarding the duration of the Covid-19 epidemic. None of the members of the FOMC are scientists, so that candor was refreshing in the midst of an election season. It was also expensive to stock market bulls, and I believe caution is warranted here.

Real Money readers are looking for ideas, though, and as promised, here are some stock-specific ideas for the post-Fed, anti-Powell era of investing.

I am very worried about the rising tide of vaccine nationalism. I don't think that factor is apparent at all in the sky-high valuations of vaccine plays like Moderna (MRNA) , CureVac (CVAC) and BioNTech (BNTX) .

What happens to planet Earth if one of the nationalized players (China, for instance) is the first to successfully manufacture a vaccine? Does that leave folks in the U.S and India out in the cold?

Also, if Moderna or CureVac come up with a novel, mRNA-based approach to a vaccine, to whom will they sell it? That's the key point here, and one I don't think the market is considering.

Governments will be the purchasers of vaccines, when proven safe, and it is likely that marketing will be just as important as the science. That works in the favor of larger players like AstraZeneca (AZN) , which by definition have larger legal and marketing departments than glorified start-ups like Moderna. So, it may not be the most effective vaccine that wins, but the company with the most effective sales team.

I own Arcturus Therapeutics (ARCT) , which is currently in Phase 1/ 2 trials with Duke-NUS hospital in Singapore and also has a marketing agreement with the Israeli government. I am a big believer in ARCT's self-transcribing and replicating RNA (STARR) technology, but do their smart scientists have enough of an advantage over companies backed by the governments of China or Russia? For a Covid-19 vaccine specifically, probably not, so ARCT will have to win on the science.

One way to "punt" on that difficult question is to buy Catalent (CTLT) -- recently added to the S&P 500 to the chagrin of Tesla (TSLA) bulls -- which has manufacturing agreements with Arcturus, Moderna and AstraZeneca, among others. Marketing a Covid-19 vaccine is going to be a race the likes of which the scientific world has never seen, so perhaps sticking with a company that only makes the vaccine itself is a safer bet.

In contrast, the market's continuing fascination with "recovery plays" opens players up to bets that are anything but safe. Airlines, cruise lines and hospitality companies are still radioactive to me. If you want to "play" them, that's fine, but please remember that you are gambling, and presumably NOT with the house's money.

Also don't forget the someone will have to pay for all of this. In my opinion, banks and insurance companies have only scratched the surface of their real liability for the distress of companies (and people who work for them) in travel, tourism and hospitality.

Also, the companies (REITs, for instance) that own the properties that are rented to operating companies in the aforementioned industries still face a liability crisis.

It's a different world. Saying "it's 2020!" has become a catch-all to describe the insanity of the year, but just make sure that your portfolio is composed of sane assets for the balance of this crazy year.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Collins' firm had a position in ARCT.

TAGS: Short-selling | Drug Approvals | Federal Reserve | Investing | Markets | Politics | Stocks | Trading

More from Stocks

The Psilocybin Patent Race Is On

Debra Borchardt
Mar 6, 2021 12:30 PM EST

It feels like these companies are casting a wide net, but it makes sense to file at the beginning of this mushroom mania.

The Challenge of Short Selling

James "Rev Shark" DePorre
Mar 6, 2021 10:00 AM EST

Short selling is a powerful tool, but it is not just the inverse of going long and requires a very different mindset to do it effectively.

Kass: There Are Many Reasons to Be a Bear

Doug Kass
Mar 6, 2021 8:15 AM EST

I believe the markets are headed lower - probably not in a straight line or as steep as the last few days, but in a saw tooth fashion lower.

Bounce Takes Some of the Sting Out of a Painful Week

James "Rev Shark" DePorre
Mar 5, 2021 4:51 PM EST

It is premature to declare that the worst is over, but the intensity of the selling will go a long way toward helping a bottom to form.

The Selloff in Twilio Could Extend Deeper Into March

Bruce Kamich
Mar 5, 2021 2:30 PM EST

TWLO could bounce in the short-run but avoid the long side for now.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:38 AM EST GARY BERMAN

    The INDU and DIA

    FIBOCALL: The INDU index and the DIA The INDU ...
  • 10:44 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    "The Challenge of Short-Selling"
  • 08:40 AM EST PAUL PRICE

    Recent Pick SpartanNash (SPTN) Raised Its Quarterly Payout by 3.9%

  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login